Abliva AB
STO:ABLI
Abliva AB
STO:ABLI
Price:
0.444
SEK
0.23%
Market Cap:
kr715.7m
Abliva AB
Abliva AB is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of primary mitochondrial diseases. The company is headquartered in Lund, Skane. The company went IPO on 2008-10-03. The firm focuses on the development of novel treatments for primary mitochondrial diseases.
Abliva AB
Business Overview
Abliva AB is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of primary mitochondrial diseases. The company is headquartered in Lund, Skane. The company went IPO on 2008-10-03. The firm focuses on the development of novel treatments for primary mitochondrial diseases.
No Earnings Calls Available
Management
Dr. Ellen K. Donnelly Ph.D.
Chief Executive Officer
No Bio Available
Ms. Catharina Jz Johansson
Deputy CEO, CFO & VP of Investor Relations
No Bio Available
Dr. Eskil Elmér M.D., Ph.D.
Chief Scientific Officer & VP of Discovery
No Bio Available
Ms. Eleonor Åsander Frostner
Communications Officer & Lab Manager
No Bio Available
Dr. Magnus Hansson
Chief Medical Officer and VP of Preclinical & Clinical Development
No Bio Available
Mr. Dag Nesse
Vice President of Clinical Operations
No Bio Available
Dr. Lars Vedin
Consultant
No Bio Available
